Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, today announced that President and Chief Executive Officer Chuck Wilson will present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on September 29, 2016 at 12:30 pm ET. The conference is being held September 28-29, 2016 at the Lotte New York Palace in New York.
Unum uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. The Company’s lead program, which combines Unum’s proprietary Antibody-Coupled T-cell Receptor (ACTR) technology with rituximab, is in Phase 1 clinical testing to assess its safety and efficacy. The company is headquartered in Cambridge, MA. For more information, visit www.unumrx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160921005322/en/Business Wire
Last updated on: 21/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.